



IDT appoints Michael Kotsanis as Director

... IDT appoints Michael Kotsanis as independent, non-executive Director, with effect from 23 March 2020

23 March 2020, Melbourne: IDT Australia Limited (ASX: IDT) today announced that Mr Michael Kotsanis has been appointed as an independent non-executive Director, effective 23 March 2020.

Michael has more than 30 years of strategic and operational experience in the global pharmaceutical industry. Since November 2014 he has served as CEO of Acrux Ltd and prior to that was the Chief Commercial Officer and a Board Member of Synthron Holding BV, a Dutch based international pharmaceutical company. He served as President, Europe, Middle East and Africa for Hospira, the global leader in generic injectable pharmaceuticals prior to its acquisition by Pfizer, where he was responsible for delivering US\$500+ million annual revenue. Michael joined Hospira following its acquisition of Mayne Pharma in 2007, where he had served as President, Asia Pacific from 2002, joining Mayne after their acquisition of FH Faulding in 2001, where he was Vice President of the Australia and New Zealand pharmaceutical business.

Michael has formerly been a Board Member of the European Generics Association and a Director of the Generic Medicines Industry of Australia.

“Michael’s appointment follows a comprehensive search process and his commercial pharmaceuticals background complements the strengths of the other Board members and the Company’s strategy” said IDT’s Chair, Mr Alan Fisher.

An Appendix 3X Initial Director’s Interest Notice is attached

ENDS

For further information please contact:

IDT Australia Limited
Dr David Sparling – Chief Executive Officer
(03) 9801 8888

Disclosure: This ASX announcement was authorised for release by the chair, Mr Alan Fisher.

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	IDT Australia Limited
ABN	66 006 522 970

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Michael John Kotsanis
Date of appointment	23 March 2020

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities

Nil

Appendix 3X
Initial Director's Interest Notice

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest	Number & class of Securities
<p>Note: Provide details of the circumstances giving rise to the relevant interest.</p> <p>Not applicable</p>	<p>Not applicable</p>

Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Nil
Nature of interest	
Name of registered holder (if issued securities)	
No. and class of securities to which interest relates	

+ See chapter 19 for defined terms.